Table 1 PPL expression in experimental mouse models of hepatic injury
From: Cholestasis induces reversible accumulation of periplakin in mouse liver
| Â | Triggers/Treatments | Â | Serum markers | PPL | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|  |  |  | N†| ALT(IU/L) | AST(IU/L) | T-Bil(mg/L) | N‡ | T-BA(μmol/L) | N§ | mRNA(qPCR) | Protein(IHC*) |
Dietary bile acid |  CA | 0% | 5 | 25±2 | 79±16 | 0.06±0.01 | 5 | 6.4±1.3 | 8 | 1.0±0.30 | - |
|  |  (7 d) | 0.1% | 5 | 45±9 | 107±13 | 0.06±0.01 | 5 | 11±4.3 | 7 | 1.7±0.87 | - |
|  |  | 0.25% | 4 | 494±133 | 496±192 | 0.08±0.01 | 4 | 49±21 | 8 | 3.8±1.7 | + |
|  |  | 1.0% | 5 | 428±186 | 315±120 | 0.89±0.43 | 5 | 460±65 | 8 | 9.5±4.1 | ++++ |
Dietary detergent |  SDS | 0% | 5 | 33±3 | 75±12 | 0.05±0.01 | 5 | 6.3±3.1 | 5 | 1.0±0.57 | - |
|  |  (7 d) | 0.1% | 5 | 36±11 | 94±21 | 0.05±0.01 | 5 | 7.4±1.9 | 5 | 1.6±0.52 | - |
|  |  | 0.25% | 5 | 32±5 | 117±23 | 0.06±0.01 | 5 | 8.8±2.4 | 4 | 1.7±0.66 | - |
|  |  | 1.0% | 5 | 43±6 | 219±23 | 0.11±0.02 | 5 | 6.0±1.5 | 4 | 4.0±2.1 | - |
Acute hepatitis |  ConA | Initial | 4 | 33±1 | 107±10 | 0.08±0.01 | 4 | 3.1±1.3 | 4 | 1.0±0.20 | - |
(T cell-mediated) |  | Veh 8 h | 6 | 34±8 | 111±25 | 0.08±0.01 | 6 | 3.6±0.76 | 6 | 2.8±0.73 | - |
|  |  | ConA 8 h | 5 | 4927±3414 | 3181±2121 | 0.55±0.10 | 5 | 27±14 | 5 | 3.5±1.9 | - |
|  |  | Veh 24 h | 5 | 38±8 | 120±30 | 0.08±0.01 | 5 | 6.2±2.6 | 5 | 1.3±0.76 | - |
|  |  | ConA 24 h | 4 | 6866±813 | 6296±1025 | 0.23±0.06 | 4 | 42±9.1 | 4 | 6.7±3.4 | + |
|  |  | Veh 48 h | 5 | 35±6 | 110±28 | 0.05±0.01 | 5 | 3.2±0.78 | 4 | 1.6±0.23 | - |
|  |  | ConA 48 h | 8 | 376±201 | 423±124 | 0.10±0.02 | 8 | 14±6.8 | 8 | 2.9±0.61 | + |
Acute hepatitis |  CCl4 | Veh 24 h | 5 | 42±25 | 169±43 | 0.08±0.02 | 5 | 2.4±0.53 | 5 | 1.0±0.23 | - |
(ROS-mediated) |  | CCl4 24 h | 5 | 7774±2745 | 5235±1775 | 0.21±0.03 | 5 | 69±15 | 5 | 2.0±0.94 | - |
|  |  | Veh 48 h | 5 | 36±3 | 117±32 | 0.06±0.01 | 5 | 3.3±0.90 | 5 | 1.1±0.42 | - |
|  |  | CCl4 48 h | 5 | 11376±2964 | 7140±2472 | 0.19±0.03 | 5 | 120±20 | 5 | 7.6±1.8 | + |
Hepatic fibrosis |  CCl4 | Veh 4 w | 5 | 49±19 | 173±50 | 0.06±0.02 | 5 | 2.7±0.30 | 5 | 1.0±0.69 | - |
|  |  | CCl4 4 w | 5 | 346±144 | 322±39 | 0.09±0.02 | 5 | 9.8±1.5 | 5 | 1.4±0.30 | + |
Hepatic steatosis |  ob/ob | +/+ | 5 | 23±3 | 71±8 | 0.04±0.01 | 5 | 2.2±1.5 | 5 | 1.0±0.48 | - |
|  |  | ob/cob | 5 | 145±44 | 139±27 | 0.04±0.01 | 5 | 11±6.2 | 5 | 1.7±0.43 | - |
Acute cholestasis |  ANIT | Veh 48 h | 7 | 36±8 | 115±42 | 0.04±0.01 | 4 | 5.2±1.1 | 4 | 1.0±0.54 | - |
(Intrahepatic) |  | ANIT 48 h | 5 | 1807±811 | 2572±1848 | 1.2±0.88 | 5 | 710±300 | 5 | 25±5.0 | ++++ |
Chronic cholestasis |  BDL | No treat | 5 | 22±4 | 77±6 | 0.07±0.03 | 3 | 4.5±2.4 | 5 | 1.0±0.33 | - |
(Obstructive) |  | Sham 7d | 5 | 26±4 | 82±10 | 0.05±0.01 | 5 | 5.1±3.2 | 5 | 0.60±0.29 | - |
|  |  | BDL 7d | 5 | 880±316 | 936±339 | 12.4±3.6 | 5 | 800±210 | 5 | 12±1.9 | +++++ |
|  |  | Sham 21d | 5 | 27±7 | 99±27 | 0.05±0.01 | 5 | 6.0±4.0 | 5 | 0.99±0.42 | - |
|  |  | BDL 21d | 5 | 604±378 | 1174±757 | 10.3±2.5 | 5 | 1100±480 | 5 | 5.1±1.7 | +++++ |